# Cannabis and Memory — What 2026 Science Actually Shows (Short Term vs Long Term) > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-and-memory-what-2026-science-actually-shows-short-term-vs-long-term/ > **Published:** 2026-07-11T07:28:30-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:04:15-04:00 > **Clinical Summary:** 2026 clinical evidence on cannabis memory impairment, false memory formation, and terpene effects. What clinicians need to know about THC and cognition. --- ✦ New CED Clinical Relevance #57 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. ResearchNeurologyTHCMental HealthSafetyPediatricsDosing Why This Matters Clinicians need to understand the distinction between acute and chronic cannabis effects on memory to counsel patients accurately about risks at different life stages, particularly since adolescent brains show greater vulnerability to memory impairment. Recent randomized evidence on cannabinoid-terpene interactions, such as pinene’s role, can inform discussions about product selection and dosing for patients using cannabis therapeutically while trying to minimize cognitive [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/). This evidence is essential for clinicians treating patients with memory concerns, [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/), or neurodevelopmental conditions who may be considering or already using cannabis. Clinical Summary Recent evidence, including a 2026 Washington State University randomized controlled trial, clarifies the nuanced effects of cannabis on memory function across different timeframes and user populations. The research demonstrates that acute [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) impairs short-term memory performance, while long-term cognitive effects appear more variable and may depend on age of initiation, frequency of use, and specific cannabinoid-terpene profiles, particularly the role of pinene in modulating memory-related effects. Notably, the study found concerning evidence that cannabis can increase false memory formation, a clinically significant finding for patients using cannabis for medical purposes who may need to rely on accurate recall or decision-making. Age represents a critical moderating factor, with adolescent users showing potentially greater vulnerability to sustained memory impairment compared to adults, underscoring the importance of counseling younger patients about cognitive risks. These findings support a more differentiated clinical approach where temporary memory effects should be expected acutely, while patients initiating [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during adolescence warrant closer monitoring for longer-term cognitive consequences. Clinicians should discuss both acute memory impairment and the potential for false memory formation when counseling patients about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), particularly regarding occupational safety and decision-making capacity. Clinical Perspective 🧠 While emerging 2026 research provides useful mechanistic insights into how cannabis affects different memory systems, clinicians should recognize that laboratory findings on false memories and acute impairment may not fully translate to real-world patient outcomes, particularly given the substantial variability in cannabinoid and terpene profiles across commercial products. Adolescent populations warrant heightened concern given ongoing brain development, yet most clinical data still derives from adult studies, limiting our ability to counsel younger patients with confidence about long-term cognitive consequences. The focus on specific compounds like pinene is scientifically interesting but shouldn’t obscure the fact that whole-plant effects remain poorly characterized and individual responses vary considerably based on genetics, frequency of use, and product composition. In practice, clinicians should continue screening for memory complaints in regular cannabis users—especially those under 25—while acknowledging that current evidence doesn’t yet support population-level recommendations beyond general caution, and should discuss both acute 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20and%20Memory%20%E2%80%94%20What%202026%20Science%20Actually%20Shows%20%28Short%20Term%20vs%20Long%20Term%29%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68897)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68897)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20and%20Memory%20%E2%80%94%20What%202026%20Science%20Actually%20Shows%20%28Short%20Term%20vs%20Long%20Term%29%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68897)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Cannabis, Tics, Tourette Syndrome, and OCD Symptoms](https://cedclinic.com/cannabinoids-for-tic-disorders-ocd/) - [Cannabis for Sleep: What Actually Works?](https://cedclinic.com/cannabis-for-sleep-thc-cbd-cbn/) - [Brain Scans Reveal Voluntary Psychedelic-Like Trance Without Drugs](https://cedclinic.com/neuroimaging-study-drug-free-altered-states/) 📰 Source: [https://www.youtube.com/watch?v=InbKEFhHqXU](https://www.youtube.com/watch?v=InbKEFhHqXU) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).